Will out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Andembry is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DGDA?

The DGDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DGDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Bangladeshi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Bangladesh Medical and Dental Council (BMDC) and the DGDA verifies the active license; the DGDA application records both the prescribing physician and the dispensing facility.

Can I receive Andembry at home?

The dispensing facility must be Bangladeshi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Andembry access in Bangladesh: the DGDA named-patient pathway

How patients in the People's Republic of Bangladesh legally obtain Andembry (garadacimab-gxii) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Bangladesh access Andembry (garadacimab-gxii) for routine prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and adolescents 12 years of age and older through the DGDA named-patient pathway, a Directorate General of Drug Administration-administered mechanism that allows a Bangladeshi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BDT.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Andembry reaches patients in Bangladesh

Andembry (garadacimab, a fully human monoclonal antibody selectively inhibiting activated factor XII at the upstream entry to the kallikrein-kinin pathway from CSL Behring, FDA-approved 16 June 2025 for routine prophylaxis to prevent attacks of hereditary angioedema in patients aged 12 years and older, label resource at accessdata.fda.gov) is not listed on the Directorate General of Drug Administration registered imported drugs database at dgdagov.info/registered-imported-drugs as of 2026-06-01. Bangladesh patients access the medicine under the case-by-case Permission to Import Unregistered or Foreign Medicine for Personal or Institutional Use, administered by DGDA under Section 13 of the Drugs (Control) Ordinance 1982 read with Section 14A (which prohibits prescription of unregistered medicines absent DGDA permission), with the ordinance text at bdlaws.minlaw.gov.bd/act-623. The DGDA Guidelines on Import Procedures for Medical Products are published at dgdagov.info guidance, with the Bangladesh Trade Portal Registration for Foreign Medicine procedure at bangladeshtradeportal.gov.bd. The application is a written submission to the Director General of DGDA accompanied by a prescription from a registered medical practitioner with Bangladesh Medical and Dental Council registration, a medical report supporting the HAE indication, the patient's national identification, and a pro-forma invoice. No public DGDA service-level agreement for processing time is published; treatment is granted case by case. Each consignment requires a fresh DGDA permission letter presented to Bangladesh Customs at port of entry.

Where Andembry is dispensed in Bangladesh

Andembry is a 2 to 8 degree Celsius refrigerated biologic administered as a once-monthly subcutaneous injection. Dispensing routes through allergy and immunology services or internal medicine clinics with capacity for biologic handling, patient training on the subcutaneous injection technique, and HAE attack-tracking documentation. Bangladesh hereditary angioedema specialty experience is concentrated at the highest-tier university and private tertiary centres. Bangabandhu Sheikh Mujib Medical University Dhaka, at bsmmu.edu.bd, hosts the university Department of Internal Medicine, Haematology, and Allergy services that handle complex immunology cases. Dhaka Medical College Hospital provides general tertiary internal medicine. Among private tertiary nodes, Square Hospitals Dhaka, United Hospital Dhaka, Evercare Hospital Dhaka (formerly Apollo Hospitals Dhaka), and Labaid Specialized Hospital Dhaka are the most-frequent routes for refrigerated biologic imports under DGDA permissions. The Bangladesh Society of Medicine and the Bangladesh Society of Allergy and Immunology engage with specialty-physician training on rare conditions. No public record of a dedicated Bangladesh HAE registry or HAE specialty care centre comparable to the international US HAEA Angioedema Center model has been observed as of 2026-06-01. The dispensing facility must hold a drug licence covering refrigerated biologics.

What Andembry costs in Bangladesh

The US wholesale acquisition cost for Andembry has been reported by CSL Behring in launch materials at approximately USD 552,000 to USD 648,000 per year of routine prophylaxis at the once-monthly subcutaneous dosing schedule per the FDA-approved label, sourced from manufacturer disclosures and Drugs@FDA at accessdata.fda.gov. No public local-currency benchmark for Andembry in BDT is observed on DGDA at dgda.gov.bd or in Bangladesh hospital-pharmacy or patient-organisation reporting as of 2026-06-01, consistent with the drug not being DGDA-registered; do not estimate. Price snapshot: 2026-06-01. Cost layers stacked on the drug cost include international validated 2 to 8 degree Celsius cold-chain freight, DGDA permission and customs handling, the hospital biologic-handling fee, and the Reserve Meds concierge fee itemised separately on every firm quote. Bangladesh customs guidance referenced in the US Department of Commerce country guide at trade.gov Bangladesh guide sets a non-commercial-import threshold of USD 7,000 for individual personal-use shipments without separate import licence; for a year of Andembry the threshold is not relevant because the value exceeds the threshold and DGDA permission is the binding requirement.

Funding and access barriers for Andembry in Bangladesh

Bangladesh has no nationwide universal health insurance scheme as of 2026-06-01. The Shasthyo Surokhsha Karmasuchi pilot scheme operates in selected upazilas for below-poverty-line families; coverage of unregistered named-patient imports is not documented under the pilot. Public-sector tertiary hospitals operating under the Ministry of Health and Family Welfare procure essential drugs through national budgets and ad-hoc allocations; specialty rare-disease biologics like Andembry are not part of routine MOHFW procurement. The Honourable Prime Minister's Welfare Fund and the Honourable Prime Minister's Special Fund consider case-by-case grants for high-cost foreign-sourced treatment for citizens lacking means; Andembry-class HAE prophylactic biologics have not been the subject of any public bulletin from these funds as observed at the snapshot date. Bangladesh private insurers including Pragati Life Insurance, Delta Life Insurance, MetLife Bangladesh, Green Delta Insurance, Pioneer Insurance, and the state-owned Sadharan Bima Corporation assess unregistered named-patient imports policy by policy; private health insurance penetration in Bangladesh is low. Bangladesh's out-of-pocket share of total health expenditure consistently sits above 65 percent per WHO and National Health Accounts reporting referenced through MOHFW. The dominant funding pattern for an Andembry case is family self-pay, supported where applicable by remittance and family savings. The CSL Behring Andembry patient-assistance and pricing-support programmes operate US-only and do not extend to international named-patient imports.

Recent regulatory and access news for Andembry

The DGDA notices feed at dgda.gov.bd/all-categories-notices has not posted a garadacimab-specific notification over the last 12 months as of 2026-06-01. DGDA published the Guideline for Quality Assurance of Locally Sourced Medical Products on 2025-01-14 at dgda.portal.gov.bd policy document, which addresses local manufacturing quality rather than personal-import biologic permissions. The Government of Bangladesh has continued public consultation on a planned new medicine-regulation law to replace the 1982 Ordinance, reported by Dhaka Tribune at dhakatribune.com new law on medicine regulation; the planned law had not been gazetted at the snapshot date. No relevant local bulletins on Andembry or hereditary angioedema-class therapies in Bangladesh in the last 12 months have been observed as of 2026-06-01.

Where Reserve Meds fits in Andembry cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DGDA, and we do not replace your dispensing pharmacy. For Andembry specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bangladesh, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Andembry case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DGDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Bangladeshi tertiary specialty care concentrates at Square, Apollo Imperial, United, Evercare, and Labaid in Dhaka; the DGDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.

Next step

If your Bangladeshi physician has prescribed Andembry and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Andembry case Or message us on WhatsApp